ArticleKidney diseases (Basel, Switzerland)
Epirubicin Ameliorates Kidney Fibrosis by Inhibiting B56δ-Mediated Lipid Generation.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic kidney disease (CKD) presents a significant global health challenge, characterized by increased fibrosis and metabolic disturbances. B56δ, a regulatory B subunit of protein phosphatase 2A (PP2A), is known to mediate the activity of PP2Acα in regulating de novo lipid synthesis and the progression of kidney fibrosis. Due to the potential severe toxic side effects associated with targeting PP2Acα directly, the substrate selectivity of the regulatory B subunits makes it a more favorable alternative. Methods: Epirubicin (EPI) was identified as a high-affinity binder to B56δ through screening approaches. Its therapeutic effects were evaluated in a murine model of unilateral ureteral obstruction (UUO) and in TGF-β-stimulated NRK-52E cells. Lipid deposition, fibrotic markers, extracellular matrix accumulation, and cell viability were assessed to determine efficacy and safety. Results: Administration of EPI in UUO mice markedly reduced renal lipid accumulation and attenuated fibrosis progression. In TGF-β-treated NRK-52E cells, EPI significantly decreased lipid droplet formation and extracellular matrix deposition without exerting notable cytotoxic effects. Conclusions: Targeted inhibition of B56δ using EPI represents a promising adjunctive therapeutic strategy for CKD, effectively mitigating lipid dysmetabolism and fibrotic progression while demonstrating a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.